Zamira Australia has raised US$5.4 million to fund Companion Animal’s growth initiatives
Zamira Australia has completed a fundraising to support Companion Animal’s growth initiatives and further strengthen its balance sheet.
Zamira is an Australian animal health brand whose mission is to improve the health and well-being of animals across the world. The company is favorably positioned as a premium brand, with localized understanding and expertise – a trusted and strong Australian brand identity amongst its international competitors. The Companion Animal range is Zamira’s new line of Australian-made premium supplements for pets. Formulated by Australian vets using ethically sourced ingredients, ZamiPet helps support digestive and immune function, maintain vitality, joint health, cognitive function, skin, coat and nails, as well as helping support the reduction of stress, tension and anxiety in dogs.
Oaklins’ team in Australia acted as corporate advisor and lead manager to the raise and continues to support Zamira as they strive to become a leader in pet health and well-being, and a global leader in the supply of animal health products.
Talk to the deal team
Related deals
ABZ Seeds has been acquired by Planasa
ABZ Seeds, a renowned breeder of seed-propagated F1 hybrid strawberry varieties, has been acquired by Planasa, a global leader in breeding next-generation berry varieties, including blueberries, blackberries, raspberries and strawberries.
Learn moreDen Berk Délice accelerates growth through strategic partnership
Den Berk Délice, a leading Belgian grower of specialty tomatoes, has entered a strategic partnership with Egeria, an independent investment firm, to realize its next growth phase.
Learn moreXiel Limited has been acquired by MIS Healthcare
MIS Healthcare, a leading distributor in medical imaging, has successfully acquired Xiel Limited. This strategic acquisition merges MIS Healthcare’s extensive radiotherapy portfolio with Xiel’s specialized expertise in nuclear medicine, radiotherapy and diagnostic radiology. The merger strengthens both companies’ positions in the rapidly growing fields of oncology and nuclear medicine, promising to deliver exceptional value to the healthcare community in the UK and Ireland.
Learn more